This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Editorial

. 2021 Dec 21;42(48):4902-4904.

doi: 10.1093/eurheartj/ehab561.

SGLT2 inhibitors: the story continues to unfold

Ileana L Piña¹

Affiliations

PMID: 34423356
DOI: 10.1093/eurheartj/ehab561

Editorial

SGLT2 inhibitors: the story continues to unfold

Ileana L Piña. Eur Heart J. 2021.

. 2021 Dec 21;42(48):4902-4904.

doi: 10.1093/eurheartj/ehab561.

Author

Ileana L Piña¹

Affiliation

¹ Central Michigan University College of Medicine, Midlands, MI, USA.

PMID: 34423356
DOI: 10.1093/eurheartj/ehab561

No abstract available

PubMed Disclaimer

Comment on

Effects of canagliflozin on serum potassium in people with diabetes and chronic kidney disease: the CREDENCE trial.
Neuen BL, Oshima M, Perkovic V, Agarwal R, Arnott C, Bakris G, Cannon CP, Charytan DM, Edwards R, Górriz JL, Jardine MJ, Levin A, Neal B, De Nicola L, Pollock C, Rosenthal N, Wheeler DC, Mahaffey KW, Heerspink HJL. Neuen BL, et al. Eur Heart J. 2021 Dec 21;42(48):4891-4901. doi: 10.1093/eurheartj/ehab497. Eur Heart J. 2021. PMID: 34423370 Clinical Trial.

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions

Substances

Actions
Actions

LinkOut - more resources

Full Text Sources
- Ovid Technologies, Inc.
- Silverchair Information Systems
Medical
- MedlinePlus Health Information